Clinical Trials Browser

Phase 1/2 × adagrasib × 90 days × Clear all

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms